Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL4034014 | 0.98 | FDPS (0.52) | FDPSMEN1MAPK10GFERKMT2A | |
| SCHEMBL28673545 | 0.92 | CYP2C19 (0.47) | FDPSMEN1MAPK10GFERKMT2A | |
| SCHEMBL19581187 | 0.86 | KDM4E (0.43) | FDPSMEN1MAPK10GFERKMT2A | |
| SCHEMBL19581183 | 0.86 | KDM4E (0.43) | FDPSMEN1MAPK10GFERKMT2A | |
| Dichloroacetic Acid SCHEMBL10510997 | 0.84 | POLB (0.51) | FDPSMEN1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL24567486 | 0.83 | FDPS (0.50) | FDPSMEN1MAPK10GFERKMT2A | |
| SCHEMBL9641327 | 0.83 | FDPS (0.50) | FDPSMEN1MAPK10GFERKMT2A | |
| SCHEMBL3644137 | 0.83 | FDPS (0.55) | FDPSMEN1MAPK10GFERKMT2A | |
| SCHEMBL25083172 | 0.83 | FDPS (0.50) | FDPSMEN1MAPK10GFERKMT2A | |
| SCHEMBL16126083 | 0.83 | FDPS (0.50) | FDPSMEN1MAPK10GFERKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491918-B | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2023-10-24 | — | — | CN | claimed |
| US-20200035418-A1 | PASSIVATION OF DEFECTS IN PEROVSKITE MATERIALS FOR IMPROVED SOLAR CELL EFFICIENCY AND STABILITY | NUTECH VENTURES | 2020-01-30 | — | — | US | claimed |
| WO-2018152494-A1 | PASSIVATION OF DEFECTS IN PEROVSKITE MATERIALS FOR IMPROVED SOLAR CELL EFFICIENCY AND STABILITY | NUTECH VENTURES (US) | 2018-08-23 | — | — | WO | claimed |
| CN-108026099-A | The aminopyridine compounds substituted through heteroaryl | 百时美施贵宝公司 | 2018-05-11 | — | — | CN | claimed |
| CN-119684291-A | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| CN-114560886-B | Precursor aminopyridyl Ni (II) compound for information storage material | 许昌学院 | 2024-03-19 | — | — | CN | disclosed |
| WO-2024054469-A1 | ISOQUINOLONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-6194490-B1 | MIXTURES OF EPOXIDES WITH ANHYDRIDES AND CURING | VANTICO, INC. | 2001-02-27 | — | — | US | disclosed |
| CN-1277198-A | New bicyclo aminopyrazineone compound, its producing process and medical composition containing them | ADIR (FR) | 2000-12-20 | — | — | CN | disclosed |
| EP-1058702-A1 | CURABLE COMPOSITION COMPRISING EPOXIDISED NATURAL OILS | Vantico AG (CH) | 2000-12-13 | — | — | EP | disclosed |
| EP-0977743-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-02-09 | — | — | EP | disclosed |
| EP-0949230-A1 | PROCESSES FOR PRODUCING ALKENYL-SUBSTITUTED AROMATIC HYDROCARBONS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999043729-A1 | CURABLE COMPOSITION COMPRISING EPOXIDISED NATURAL OILS | VANTICO AG (CH) | 1999-09-02 | — | — | WO | disclosed |
| WO-1998049152-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0305184-A1 | Pyrimidines or their pharmaceutically acceptable salts thereof | MITSUI PHARMACEUTICALS, INC. (JP) | 1989-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | FDPS 2194/4885MEN1 641/4885MAPK10 1613/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | FDPS 2360/4885MEN1 2805/4885MAPK10 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.